Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Niagen Bioscience signs license deal with Haukeland University (SeekingAlpha) +++ NIAGEN BIOSCIENCE Aktie -4,55%

SUMITOMO PHARMA Aktie

 >SUMITOMO PHARMA Aktienkurs 
5.3 EUR    (Tradegate)
Ask: 5.4 EUR / 925 Stück
Bid: 5.2 EUR / 963 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>SUMITOMO PHARMA Performance
1 Woche: 0%
1 Monat: +18,1%
3 Monate: +69,6%
6 Monate: +70,6%
1 Jahr: +150,0%
laufendes Jahr: +67,6%
>SUMITOMO PHARMA Aktie
Name:  SUMITOMO PHARMA CO. LTD.
Land:  Japan
Sektor:  Gesundheit
ISIN/ Wkn:  JP3495000006 / 858257
Symbol/ Ticker:  DPM (Frankfurt)
Kürzel:  FRA:DPM, ETR:DPM, DPM:GR
Index:  Nikkei225
Webseite:  https://www.sumitomo-phar..
Marktkapitalisierung:  2530 Mio. EUR
Umsatz:  344344.39 Mio. EUR
EBITDA:  33309.45 Mio. EUR
Gewinn je Aktie:  0.311 EUR
Schulden:  263695.47 Mio. EUR
Liquide Mittel:  19961.49 Mio. EUR
Umsatz-/ Gewinnwachstum:  32.8% / -
KGV/ KGV lG:  17.73 / -
KUV/ KBV/ PEG:  1.05 / 2.47 / -
Gewinnm./ Eigenkapitalr.:  5.93% / 14.52%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Div. Historie:  30.03.23 - 0.04865€
29.09.22 - 0.09982€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  SUMITOMO PHARMA
Letzte Datenerhebung:  08.07.25
>Eigentümer
Aktien: 397.29 Mio. St.
f.h. Aktien: 180.16 Mio. St.
Insider Eigner: 57.45%
Instit. Eigner: 17.54%
Leerverk. Aktien: -
>Peer Group

 
12.06.25 - 17:33
Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis (PR Newswire)
 
– Nuvisertib (TP-3654), an investigational highly selective oral PIM1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – – Nuvisertib demonstrated symptom and spleen responses correlating with cytokine modulation in the preliminary Phase 1/2......
05.06.25 - 12:48
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo′s Canadian Portfolio (GlobeNewswire EN)
 
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA's affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE®, ORGOVYX® and vibegron, the “Products”). For the year ended March 2025, the Products generated C$11.2 million in revenue....
13.05.25 - 07:36
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update (Business Wire)
 
TWYMEEG® consolidated gross sales in Japan for Sumitomo Pharma Fiscal Year 20241 achieved JPY 7.6 billion (EUR 47,2 million)2, in line with Sumitomo Pharma's latest guidance3 Sumitomo Pharma forecast for TWYMEEG®'s FY 20254 of JPY 11.2 billion (EUR 69,4 million2), representing a 47% increase over FY 2024 sales In FY2024, Poxel started receiving 10% royalties on TWYMEEG® net sales, and from FY2025 5 anticipates receiving escalating double-digit royalties and additional sales-based payments upon achievement of contractual sales thresholds Regulatory approval on April 8, 2025, by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enabling Sumitomo Pharma to immediately start promoting the use of TWYMEEG® (Imeglimin) in type 2 diabetic patients with moderate to severe renal impairment Ongoing discussions with 1/ creditors to ensure continuity of the Company's operations and 2/ potential partners for the development of pipeline products LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL S...
17.04.25 - 07:01
Sumitomo Pharma Poised to Jump on Stem Cell Research Results (Bloomberg)
 
Sumitomo Pharma Co. is set to rise by the daily limit in Tokyo after results of a study showed the safety and potential benefits of stem cells used to treat Parkinson's disease....
14.04.25 - 15:01
Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib (PR Newswire)
 
– Partnership with the NCI will build on the promising preliminary clinical activity of enzomenib in acute leukemia to further explore potential activity in other cancers – MARLBOROUGH, Mass., April 14, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced it has......
01.04.25 - 22:18
Japan′s Marubeni to buy Sumitomo Pharma′s Asia business for $300m (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
27.03.25 - 23:31
XFRA : DIVIDEND/INTEREST INFORMATION - 28.03.2025 - JP3495000006 (XETRA)
 
Das Instrument DPM JP3495000006 SUMITOMO PHARMA CO. LTD. EQUITY wird ex Dividende/Zinsen gehandelt am 28.03.2025 The instrument DPM JP3495000006 SUMITOMO PHARMA CO. LTD. EQUITY has its ex-dividend/interest day on 28.03.2025...
23.12.24 - 15:03
Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia (PR Newswire)
 
– GEMTESA® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug......
26.09.24 - 23:49
XFRA : DIVIDEND/INTEREST INFORMATION - 27.09.2024 - JP3495000006 (XETRA)
 
Das Instrument DPM JP3495000006 SUMITOMO PHARMA CO. LTD. EQUITY wird ex Dividende/Zinsen gehandelt am 27.09.2024 The instrument DPM JP3495000006 SUMITOMO PHARMA CO. LTD. EQUITY has its ex-dividend/interest day on 27.09.2024...
07.08.24 - 08:09
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan (Business Wire)
 
Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...
25.06.24 - 23:42
After U.S. job cuts, Sumitomo Pharma eyes layoffs in Japan (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ich brauche keine Lobhudeleien. Ich habe schon zwei so genannte Jubiläumssendungen mit so viel Verlogenheit erlebt, daß ich keine dritte mehr möchte. - Karl Moik
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!